SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Acumen Pharmaceuticals Reports Third-Quarter 2026 Financial Results

The company expects to report topline results from its Phase 2 ALTITUDE-AD study of sabirnetug (ACU193).

ABOS

Related stories